We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ACHONDROPLASIA TREATMENT MARKET ANALYSIS

Achondroplasia Treatment Market, By Treatment Type (Vosoritide, Human Growth Hormone, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies , Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

  • Published In : Jul 2023
  • Code : CMI4161
  • Pages :207
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Achondroplasia Treatment MarketSize and Trends

The global achondroplasia treatment market is estimated to be valued at US$ 127.8 million in 2023 and is expected to exhibit a CAGR of 36.5% during the forecast period (2023-2030).

Global Achondroplasia Treatment Market Segmentation:

The global achondroplasia treatment market report is segmented into Treatment Type, Route of Administration, Distribution Channel, and Region.

  • By Treatment Type, the market is segmented into vosoritide, human growth hormone, and others. Out of which, the vosoritide segment is expected to hold a dominant position in the global achondroplasia treatment market during the forecast period, and this is attributed to prompt treatment can lead to proper recovery.
  • By Route of Administration, the market is segmented into oral and parenteral. Out of which, the parenteral segement is expected to dominate the market over the forecast period, and this is attributed to on set of action is more than oral route.
  • By Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacies is expected to dominate the market over the forecast period and this is attributed to prevention, diagnosis, multidisciplinary treatment, supportive care, research, and education.

Global Achondroplasia Treatment Market- Driver

  • Increased Incidence of Achondroplasia: The growing prevalence of achondroplasia is projected to drive the market growth during the forecast period. For instance, as per the data published by the European Medicines Agency in June 2021, it is projected that 350 children are born with achondroplasia each year in Europe. This boosts the market growth.
  • Increasing Drug Approvals and Launches: The increasing number of drug approvals and launches by major market players is expected to drive the market growth. For instance, In January 2022, Ascendis Pharma A/S manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology announced ,that the European Commission (EC) had approved TransCon hGH as a once-weekly subcutaneous injection to treat pediatric patients experiencing growth failure due to insufficient endogenous growth hormone secretion or growth hormone deficiency. TransCon hGH contains Somatropin, which delivers unmodified Somatropin (hGH) to the body in therapeutic quantities.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.